Home

Chris Nolet

CIK 1782814 · last filed 2026-06-22

Chris Nolet is a corporate insider who has filed 23 SEC Form 4 insider transactions across 5 companies since 2019. The most recent filing, for AVBP, was dated Jun 22, 2026. Current disclosed insider exposure totals $260 across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$260

Companies

5

Total Filings

23

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BOULEVARD
NEWARK, CA 94560
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AVBP Director — $29.00 — $0 3 2026-06-22
JSPRW Director 32,500 $0.01 $260 $0 5 2025-07-03
Revance Therapeutics, Inc. (RVNC) Delisted Director 0 $3.65 $0 $0 8 2025-02-06
POLARITYTE, INC. (PTE) Delisted Director 14,403 $0.24 $3.5K $0 4 2023-01-17
Viela Bio, Inc. (VIE) Delisted Director — — — $0 2 2021-03-15

Recent Filings

23 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-22 AVBP Grant (A) — $0 EDGAR
2025-07-03 JSPRW Grant (A) — $0 EDGAR
2025-06-20 AVBP Grant (A) — $0 EDGAR
2025-02-06 Revance Therapeutics, Inc. (RVNC) Delisted Mixed −43,606 -$104.4K EDGAR
2024-06-10 JSPRW Grant (A) — $0 EDGAR
2024-05-03 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +15,000 $0 EDGAR
2024-01-29 AVBP Grant (A) — $0 EDGAR
2023-06-08 JSPRW Grant (A) — $0 EDGAR
2023-05-05 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +3,534 $0 EDGAR
2023-01-17 POLARITYTE, INC. (PTE) Delisted Exer (M) −36,497 $0 EDGAR
Showing 1–10 of 23
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.